Floatz logo

Cyclophosphamide

Chordoma

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Chordoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Zoledronate
University of Florida
Phase 1/2CCC
Taek-Vac-Herby
Bavarian Nordic
Phase 1CC

View all 15 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →